File Download
  Links for fulltext
     (May Require Subscription)

Article: Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia

TitleReduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia
Authors
Keywordscardiac MR
chelation therapy
ferritin
heart
hemosiderin
iron overload
MRI
RR2
thalassemia
Issue Date2011
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/1053-1807/
Citation
Journal Of Magnetic Resonance Imaging, 2011, v. 33 n. 6, p. 1510-1516 How to Cite?
AbstractPurpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short-term changes in myocardial storage iron produced by iron-chelating therapy in transfusion-dependent thalassemia patients. Materials and Methods: A single-breathhold multi-echo fast spin-echo sequence was implemented at 3 Tesla (T) to estimate RR2 by acquiring signal decays with interecho times of 5, 9 and 13 ms. Transfusion-dependent thalassemia patients (N = 8) were examined immediately before suspending iron-chelating therapy for 1 week (Day 0), after a 1-week suspension of chelation (Day 7), and after a 1-week resumption of chelation (Day 14). Results: The mean percent changes in RR2, R2, and R2* off chelation (between Day 0 and 7) were 11.9 ± 8.9%, 5.4 ± 7.7% and -4.4 ± 25.0%; and, after resuming chelation (between Day 7 and 14), -10.6 ± 13.9%, -8.9 ± 8.0% and -8.5 ± 24.3%, respectively. Significant differences in R2 and RR2 were observed between Day 0 and 7, and between Day 7 and 14, with the greatest proportional changes in RR2. No significant differences in R2* were found. Conclusion: These initial results demonstrate that significant differences in RR2 are detectable after a single week of changes in iron-chelating therapy, likely as a result of superior sensitivity to soluble ferritin iron, which is in close equilibrium with the chelatable cytosolic iron pool. RR2 measurement may provide a new means of monitoring the short-term effectiveness of iron-chelating agents in patients with myocardial iron overload. Copyright © 2011 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/139127
ISSN
2021 Impact Factor: 5.119
2020 SCImago Journal Rankings: 1.563
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
Hong Kong Research Grant CouncilGRF7794/07M
Hong Kong Children Thalassaemia Foundation2007/02
National Institutes of HealthR01-DK069373
R01-DK066251
R37-DK049108
R01-DK049108
American Heart Association0730143N
Funding Information:

Contract grant sponsor: Hong Kong Research Grant Council; Contract grant number: GRF7794/07M; Contract grant sponsor: Hong Kong Children Thalassaemia Foundation; Contract grant number: 2007/02; Contract grant sponsor: National Institutes of Health; Contract grant numbers: R01-DK069373, R01-DK066251, R37-DK049108, R01-DK049108; Contract grant sponsor: American Heart Association; Contract grant number: 0730143N.

References

 

DC FieldValueLanguage
dc.contributor.authorCheung, JSen_HK
dc.contributor.authorAu, WYen_HK
dc.contributor.authorHa, SYen_HK
dc.contributor.authorKim, Den_HK
dc.contributor.authorJensen, JHen_HK
dc.contributor.authorZhou, IYen_HK
dc.contributor.authorCheung, MMen_HK
dc.contributor.authorWu, Yen_HK
dc.contributor.authorGuo, Hen_HK
dc.contributor.authorKhong, PLen_HK
dc.contributor.authorBrown, TRen_HK
dc.contributor.authorBrittenham, GMen_HK
dc.contributor.authorWu, EXen_HK
dc.date.accessioned2011-09-23T05:45:34Z-
dc.date.available2011-09-23T05:45:34Z-
dc.date.issued2011en_HK
dc.identifier.citationJournal Of Magnetic Resonance Imaging, 2011, v. 33 n. 6, p. 1510-1516en_HK
dc.identifier.issn1053-1807en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139127-
dc.description.abstractPurpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short-term changes in myocardial storage iron produced by iron-chelating therapy in transfusion-dependent thalassemia patients. Materials and Methods: A single-breathhold multi-echo fast spin-echo sequence was implemented at 3 Tesla (T) to estimate RR2 by acquiring signal decays with interecho times of 5, 9 and 13 ms. Transfusion-dependent thalassemia patients (N = 8) were examined immediately before suspending iron-chelating therapy for 1 week (Day 0), after a 1-week suspension of chelation (Day 7), and after a 1-week resumption of chelation (Day 14). Results: The mean percent changes in RR2, R2, and R2* off chelation (between Day 0 and 7) were 11.9 ± 8.9%, 5.4 ± 7.7% and -4.4 ± 25.0%; and, after resuming chelation (between Day 7 and 14), -10.6 ± 13.9%, -8.9 ± 8.0% and -8.5 ± 24.3%, respectively. Significant differences in R2 and RR2 were observed between Day 0 and 7, and between Day 7 and 14, with the greatest proportional changes in RR2. No significant differences in R2* were found. Conclusion: These initial results demonstrate that significant differences in RR2 are detectable after a single week of changes in iron-chelating therapy, likely as a result of superior sensitivity to soluble ferritin iron, which is in close equilibrium with the chelatable cytosolic iron pool. RR2 measurement may provide a new means of monitoring the short-term effectiveness of iron-chelating agents in patients with myocardial iron overload. Copyright © 2011 Wiley-Liss, Inc.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/1053-1807/en_HK
dc.relation.ispartofJournal of Magnetic Resonance Imagingen_HK
dc.rightsJournal of Magnetic Resonance Imaging. Copyright © John Wiley & Sons, Inc.-
dc.subjectcardiac MRen_HK
dc.subjectchelation therapyen_HK
dc.subjectferritinen_HK
dc.subjecthearten_HK
dc.subjecthemosiderinen_HK
dc.subjectiron overloaden_HK
dc.subjectMRIen_HK
dc.subjectRR2en_HK
dc.subjectthalassemiaen_HK
dc.subject.meshBlood Transfusion-
dc.subject.meshChelating Agents - pharmacology-
dc.subject.meshIron - chemistry-
dc.subject.meshMyocardium - pathology-
dc.subject.meshThalassemia - diagnosis - pathology-
dc.titleReduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemiaen_HK
dc.typeArticleen_HK
dc.identifier.emailZhou, IY: izhou@hku.hken_HK
dc.identifier.emailKhong, PL: plkhong@hkucc.hku.hken_HK
dc.identifier.emailWu, EX: ewu1@hkucc.hku.hken_HK
dc.identifier.authorityZhou, IY=rp01739en_HK
dc.identifier.authorityKhong, PL=rp00467en_HK
dc.identifier.authorityWu, EX=rp00193en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/jmri.22553en_HK
dc.identifier.pmid21591022-
dc.identifier.pmcidPMC3098046-
dc.identifier.scopuseid_2-s2.0-79958254314en_HK
dc.identifier.hkuros192054en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79958254314&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume33en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1510en_HK
dc.identifier.epage1516en_HK
dc.identifier.isiWOS:000291267700028-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridCheung, JS=16174280400en_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridHa, SY=7202501115en_HK
dc.identifier.scopusauthoridKim, D=8524290700en_HK
dc.identifier.scopusauthoridJensen, JH=7404521984en_HK
dc.identifier.scopusauthoridZhou, IY=35424838500en_HK
dc.identifier.scopusauthoridCheung, MM=24333907800en_HK
dc.identifier.scopusauthoridWu, Y=35782366500en_HK
dc.identifier.scopusauthoridGuo, H=55468659900en_HK
dc.identifier.scopusauthoridKhong, PL=7006693233en_HK
dc.identifier.scopusauthoridBrown, TR=7404319370en_HK
dc.identifier.scopusauthoridBrittenham, GM=7005583587en_HK
dc.identifier.scopusauthoridWu, EX=7202128034en_HK
dc.identifier.issnl1053-1807-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats